Tao Ya-Xiong, Mizrachi Dario, Segaloff Deborah L
Department of Physiology and Biophysics, The University of Iowa, Iowa City, Iowa 52242, USA.
Mol Endocrinol. 2002 Aug;16(8):1881-92. doi: 10.1210/me.2001-0199.
Although a large number of naturally occurring activating mutations of the human LH receptor (hLHR) and human TSH receptor (hTSHR) have been identified, only one activating mutation of the human FSH receptor (hFSHR) has been found. Furthermore, mutations of several residues within the i3/transmembrane domain (TM) 6 region of the hFSHR that were done based upon known constitutively activating mutations of the human LHR were found to have no effect on hFSHR signaling. One of the hFSHR mutations examined in this context was the substitution of a highly conserved aspartate (D581) in TM6 with glycine. We show herein that although the basal activity of the rat FSHR (rFSHR) is similar to the hFSHR, mutation of the comparable residue (D580) in the rFSHR causes marked constitutive activation. Taking advantage of the high degree of amino acid identity between the rat and human FSHRs, we have used chimeras and point substitutions to determine the precise residues that suppress or permit constitutive activity by the D580/581G mutation. Thus, the simultaneous substitution of M576 in TM6 and H615 in TM7 of the hFSHR with the cognate rFSHR residues (threonine and tyrosine, respectively) now renders the hFSHR(D581G) mutant constitutively active. Conversely, the substitution of Y614 of the rFSHR with the cognate hFSHR residue (histidine) fully suppresses the constitutive activity of the rFSHR (D580G) mutant. Computer models of the human and rat FSHRs and mutants thereof were created based upon the crystal structure of rhodopsin. These models suggest that differences in hydrophobic interactions between TMs 6 and 7 of the rat and human FSHRs may account for the ability of TM6 of the rat, but not human, FSHR to adopt an active conformation as a result of the D580/581G mutation.
尽管已鉴定出大量人类促黄体生成素受体(hLHR)和人类促甲状腺激素受体(hTSHR)的天然激活突变,但仅发现了一种人类促卵泡激素受体(hFSHR)的激活突变。此外,基于人类促黄体生成素受体已知的组成性激活突变,对hFSHR的i3/跨膜结构域(TM)6区域内的几个残基进行突变,发现对hFSHR信号传导没有影响。在此背景下检测的hFSHR突变之一是TM6中高度保守的天冬氨酸(D581)被甘氨酸取代。我们在此表明,尽管大鼠促卵泡激素受体(rFSHR)的基础活性与hFSHR相似,但rFSHR中可比残基(D580)的突变会导致明显的组成性激活。利用大鼠和人类促卵泡激素受体之间高度的氨基酸同一性,我们使用嵌合体和点突变来确定通过D580/581G突变抑制或允许组成性活性的确切残基。因此,将hFSHR的TM6中的M576和TM7中的H615同时替换为同源的rFSHR残基(分别为苏氨酸和酪氨酸),现在使hFSHR(D581G)突变体具有组成性活性。相反,将rFSHR的Y614替换为同源的hFSHR残基(组氨酸)可完全抑制rFSHR(D580G)突变体的组成性活性。基于视紫红质的晶体结构创建了人类和大鼠促卵泡激素受体及其突变体的计算机模型。这些模型表明,大鼠和人类促卵泡激素受体的TM6和TM7之间疏水相互作用的差异可能解释了大鼠而非人类促卵泡激素受体的TM6由于D580/581G突变而采用活性构象的能力。